Literature DB >> 7588250

Intermittent parathyroid hormone treatment increases osteoblast number, steady state messenger ribonucleic acid levels for osteocalcin, and bone formation in tibial metaphysis of hypophysectomized female rats.

I U Schmidt1, H Dobnig, R T Turner.   

Abstract

The effects of GH and PTH on cancellous histomorphometry were determined in the proximal tibial metaphysis of hypophysectomized (HYPOX) sexually mature female rats. HYPOX resulted in uterine atrophy and a loss in body weight. Longitudinal bone growth ceased and bone formation was greatly reduced. There were decreases in cancellous bone area, trabecular number, and trabecular thickness. Intermittent treatment with GH did not influence uterine weight in HYPOX rats. However, GH resulted in resumption of whole body weight gain, as well as maintenance of normal longitudinal bone growth. Additionally, GH partially maintained bone formation in HY POX rats and did not have a significant effect on steady state messenger RNA levels for osteocalcin. Intermittent treatment with PTH had no effect on whole body weight gain, uterine weight, or longitudinal bone growth. In contrast, PTH increased bone formation compared with the baseline, HYPOX, and GH-treated HYPOX rats, and dramatically increased osteocalcin messenger RNA levels compared with the latter two groups. The increased bone formation was primarily due to an increase in osteoblast number; the mineral apposition rate, an index of osteoblast activity, was increased compared with control and GH-treated rats but not compared with baseline values. Interestingly, neither treatment influenced indices of bone resorption.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7588250     DOI: 10.1210/endo.136.11.7588250

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  27 in total

1.  Overexpression of the transcriptional factor Runx2 in osteoblasts abolishes the anabolic effect of parathyroid hormone in vivo.

Authors:  Didier Merciris; Caroline Marty; Corinne Collet; Marie-Christine de Vernejoul; Valerie Geoffroy
Journal:  Am J Pathol       Date:  2007-05       Impact factor: 4.307

Review 2.  The immune system and bone.

Authors:  Roberto Pacifici
Journal:  Arch Biochem Biophys       Date:  2010-06-17       Impact factor: 4.013

3.  Teriparatide increases the maturation of circulating osteoblast precursors.

Authors:  P D'Amelio; C Tamone; F Sassi; L D'Amico; I Roato; S Patanè; M Ravazzoli; L Veneziano; R Ferracini; G P Pescarmona; G C Isaia
Journal:  Osteoporos Int       Date:  2011-05-27       Impact factor: 4.507

4.  The sclerostin-independent bone anabolic activity of intermittent PTH treatment is mediated by T-cell-produced Wnt10b.

Authors:  Jau-Yi Li; Lindsey D Walker; Abdul Malik Tyagi; Jonathan Adams; M Neale Weitzmann; Roberto Pacifici
Journal:  J Bone Miner Res       Date:  2014-01       Impact factor: 6.741

5.  Silencing of parathyroid hormone (PTH) receptor 1 in T cells blunts the bone anabolic activity of PTH.

Authors:  Brahmchetna Bedi; Jau-Yi Li; Hesham Tawfeek; Ki-Hyun Baek; Jonathan Adams; Sameera S Vangara; Ming-Kang Chang; Michaela Kneissel; M Neale Weitzmann; Roberto Pacifici
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-05       Impact factor: 11.205

6.  The basic helix loop helix transcription factor Twist1 is a novel regulator of ATF4 in osteoblasts.

Authors:  Theodora E Danciu; Yan Li; Amy Koh; Guozhi Xiao; Laurie K McCauley; Renny T Franceschi
Journal:  J Cell Biochem       Date:  2012-01       Impact factor: 4.429

Review 7.  Physical activity in the prevention and amelioration of osteoporosis in women : interaction of mechanical, hormonal and dietary factors.

Authors:  Katarina T Borer
Journal:  Sports Med       Date:  2005       Impact factor: 11.136

8.  Effects of teriparatide on serum calcium in postmenopausal women with osteoporosis previously treated with raloxifene or alendronate.

Authors:  R A Wermers; C P Recknor; F Cosman; L Xie; E V Glass; J H Krege
Journal:  Osteoporos Int       Date:  2008-02-19       Impact factor: 4.507

9.  Effects of low-dose parathyroid hormone on bone mass, turnover, and ectopic osteoinduction in a rat model for chronic alcohol abuse.

Authors:  U T Iwaniec; C H Trevisiol; G F Maddalozzo; C J Rosen; R T Turner
Journal:  Bone       Date:  2008-01-12       Impact factor: 4.398

10.  Critical role of activating transcription factor 4 in the anabolic actions of parathyroid hormone in bone.

Authors:  Shibing Yu; Renny T Franceschi; Min Luo; Jie Fan; Di Jiang; Huiling Cao; Tae-Geon Kwon; Yumei Lai; Jian Zhang; Kenneth Patrene; Kurt Hankenson; G David Roodman; Guozhi Xiao
Journal:  PLoS One       Date:  2009-10-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.